MAPT and Alzheimer disease: Ren et al. (2024) showed that overexpressed SELENOW competes with HSP70 for Tau interactions and promotes its degradation via UPS, which in turn ameliorates memory impairment and Tau protein-related pathology and delays the progression of AD in AD model mice.